Scarica l'app Stockscreener
76.85
0.50%
-0.39
Dopo l'orario di chiusura:
76.85
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Precedente Chiudi:
$77.24
Aprire:
$76.19
Volume 24 ore:
1.62M
Relative Volume:
1.09
Capitalizzazione di mercato:
$6.17B
Reddito:
$900.66M
Utile/perdita netta:
$-453.20M
Rapporto P/E:
-12.94
EPS:
-5.94
Flusso di cassa netto:
$-274.19M
1 W Prestazione:
+1.17%
1M Prestazione:
-0.08%
6M Prestazione:
+61.28%
1 anno Prestazione:
+70.63%
Intervallo 1D:
$75.64
$77.39
Intervallo di 1 settimana:
$74.22
$79.10
Portata 52W:
$35.95
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Nome
Ptc Therapeutics Inc
Settore
Industria
Telefono
(908) 222-7000
Indirizzo
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Confronta PTCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
76.85 | 6.20B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-01 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-06-17 | Iniziato | Truist | Buy |
| 2025-05-09 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-07 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-11 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Iniziato | Scotiabank | Sector Perform |
| 2024-12-13 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-08-26 | Ripresa | UBS | Buy |
| 2024-05-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-10-30 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Downgrade | Citigroup | Neutral → Sell |
| 2023-10-06 | Downgrade | Truist | Buy → Hold |
| 2023-09-18 | Downgrade | Citigroup | Buy → Neutral |
| 2023-09-15 | Downgrade | Raymond James | Outperform → Underperform |
| 2023-03-17 | Iniziato | SVB Securities | Market Perform |
| 2022-12-14 | Iniziato | Goldman | Sell |
| 2022-09-12 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-29 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-30 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-04-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-05-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Iniziato | Bernstein | Outperform |
| 2018-10-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-06-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Downgrade | JP Morgan | Neutral → Underweight |
Mostra tutto
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
PTC Therapeutics (NASDAQ:PTCT) EVP Sells $49,742.16 in Stock - MarketBeat
Neil Gregory Almstead Sells 1,026 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 1,352 Shares of Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 1,279 Shares of Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CFO Sells 2,139 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Insider Eric Pauwels Sells 1,789 Shares - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) CEO Matthew Klein Sells 5,149 Shares - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells 4,879 Shares of Stock - MarketBeat
Published on: 2026-01-09 07:20:07 - moha.gov.vn
Is PTC Therapeutics Inc. stock a safe haven assetEarnings Risk Report & Growth Focused Stock Pick Reports - ulpravda.ru
PTC Therapeutics Executives Engage in Stock Transactions - TradingView — Track All Markets
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Is PTC Therapeutics Inc. stock a defensive play in 20252025 Price Targets & Smart Investment Allocation Tips - ulpravda.ru
What dividend safety score for PTC Therapeutics Inc. stockQuarterly Market Summary & High Yield Stock Recommendations - ulpravda.ru
PTC Therapeutics Inc (NASDAQ:PTCT) Nasdaq Composite Genetic Precision - Kalkine Media
PTC THERAPEUTICS, INC. (PTCT) - MSN
PTC Therapeutics (NASDAQ:PTCT) VP Sells $171,196.30 in Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Director Emma Reeve Sells 734 Shares - MarketBeat
Glenn Md Phd Steele Jr Sells 12,000 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics Inc (PTCT) - MSN
PTC Therapeutics, Inc. (PTCT) Stock Analysis: Navigating the Biotech Frontier with a 6.64% Potential Upside - DirectorsTalk Interviews
Is PTC Therapeutics Inc. stock supported by innovation pipeline2026 world cup usa national team round of 16 star players high defensive line odds analysis expert opinion - ulpravda.ru
PTC Therapeutics (NASDAQ:PTCT) Upgraded to Buy at Wall Street Zen - MarketBeat
Matthew Klein Sells 8,089 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics CEO Sells Shares to Cover Tax Obligations - TradingView — Track All Markets
Behavioral Patterns of PTCT and Institutional Flows - Stock Traders Daily
What's Going On With Royalty Pharma Stock Wednesday? - Benzinga
Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Reach - openPR.com
Royalty Pharma Acquires Remaining Evrysdi Royalties From PTC Therapeutics - Nasdaq
Royalty Pharma Acquires Final Portion of Evrysdi Royalty from PTC Therapeutics for $240 Million - Quiver Quantitative
PTC Therapeutics Fully Monetizes Evrysdi Royalty Interest - TipRanks
PTC Therapeutics Signs Royalty Purchase Agreement Amendment With Royalty Pharma - TradingView — Track All Markets
PTC Therapeutics fully monetizes Evrysdi royalty interest - MSN
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? - AOL.com
Pacer Advisors Inc. Has $30.93 Million Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Weekly Buzz: FDA OKs Roche's Lunsumio VELO; It's No For Tolbrutinib; BioMarin, SNY Open Wallets - RTTNews
PTC Therapeutics Earnings Notes - Trefis
PTC Therapeutics (NASDAQ:PTCT) Insider Eric Pauwels Sells 20,508 Shares of Stock - MarketBeat
PTC Therapeutics Executive Eric Pauwels Sells Over 20,000 Shares - TradingView — Track All Markets
Director Reeve Emma exercised 733 shares at a strike of $46.54 and sold $57,628 worth of shares (733 units at $78.62) (SEC Form 4) - Quantisnow
PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan - Sahm
Japan Sephience Approval Could Be A Game Changer For PTC Therapeutics’ (PTCT) Rare-Disease Strategy - Yahoo Finance
PTC Therapeutics (PTCT): Valuation Check After First Japan Approval Completes Global Sephience Launch - Yahoo Finance
(PTCT) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) - GuruFocus
PTC Therapeutics' Phenylketonuria Treatment Approved in Japan - marketscreener.com
PTC Therapeutics receives Japan approval for PKU treatment Sephience By Investing.com - Investing.com Nigeria
Voya Investment Management LLC Has $17.48 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTCT Gains Japanese Approval for Phenylketonuria Treatment - GuruFocus
PTC Therapeutics receives Japan approval for PKU treatment Sephience - Investing.com
PTC Therapeutics, Inc. $PTCT Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Ptc Therapeutics Inc Azioni (PTCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):